Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Liabilities from Discontinued Operations: 2016-2018

Historic Liabilities from Discontinued Operations for Soleno Therapeutics (SLNO) over the last 2 years, with Sep 2018 value amounting to $1.8 million.

  • Soleno Therapeutics' Liabilities from Discontinued Operations rose 1448.67% to $1.8 million in Q3 2018 from the same period last year, while for Sep 2018 it was $1.8 million, marking a year-over-year increase of 1448.67%. This contributed to the annual value of $225,000 for FY2017, which is 8.69% down from last year.
  • Per Soleno Therapeutics' latest filing, its Liabilities from Discontinued Operations stood at $1.8 million for Q3 2018, which was up 66.67% from $1.1 million recorded in Q2 2018.
  • Soleno Therapeutics' Liabilities from Discontinued Operations' 5-year high stood at $1.8 million during Q3 2018, with a 5-year trough of $113,000 in Q3 2017.
  • Moreover, its 3-year median value for Liabilities from Discontinued Operations was $246,400 (2016), whereas its average is $603,343.
  • As far as peak fluctuations go, Soleno Therapeutics' Liabilities from Discontinued Operations decreased by 8.69% in 2017, and later soared by 1,448.67% in 2018.
  • Quarterly analysis of 3 years shows Soleno Therapeutics' Liabilities from Discontinued Operations stood at $246,400 in 2016, then declined by 8.69% to $225,000 in 2017, then surged by 1,448.67% to $1.8 million in 2018.
  • Its Liabilities from Discontinued Operations was $1.8 million in Q3 2018, compared to $1.1 million in Q2 2018 and $625,000 in Q1 2018.